Idenix falls hard in response to JMP downgrade

|About: Idenix Pharmaceuticals, Inc. (IDIX)|By:, SA News Editor

Five months after upgrading Idenix (IDIX -7.8%) to Market Perform, JMP has downgraded the HCV drug developer back to Underperform.

Going into today, Idenix had nearly doubled from the time of JMP's upgrade.